Valeant Pharmaceuticals International, Inc. reports that Howard B. Schiller, the company's current chief financial officer (CFO) has advised the company of his decision to step down once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant board and, with the board's continued recommendation, intends to stand for re-election as a director at the annual shareholder meeting in May. Mr. Schiller joined Valeant in December 2011 as CFO and was appointed to the board of directors of Valeant in September 2012.
The company also announced today that Anne C. Whitaker, former president and chief executive officer of Synta Pharmaceuticals, will join Valeant's Executive Management Team as executive vice president and company group chairman. Prior to joining Synta Pharmaceuticals, Ms. Whitaker served as president, North America Pharmaceuticals, at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations within the region. Previously, Ms. Whitaker held various leadership positions at GlaxoSmithKline, including senior vice president and business unit head, Cardiovascular, Metabolic and Urology (CVMU) and senior vice president of leadership and organization development.
Source: Valeant Pharmaceuticals